VAXART (VXRT)
(Delayed Data from OTC)
$0.36 USD
-0.01 (-3.84%)
Updated Aug 1, 2025 03:59 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VXRT 0.36 -0.01(-3.84%)
Will VXRT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VXRT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VXRT
Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates
VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates
VXRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
ElectroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates
Cronos Group (CRON) Reports Q4 Loss, Misses Revenue Estimates
Other News for VXRT
Vaxart announces trading on OTCQX Best Market
OTC Markets Group welcomes Vaxart to OTCQX
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Vaxart Stockholders Reject Reverse Stock Split Proposal